Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP).

× No keyword cloud information.

10 in total

Review 1. Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Authors: Roberto Stasi
Journal: Blood Transfus Date: 2010-11-26 Impact factor: 3.443

Review 2. RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).

Authors: Jenny M Despotovic; Michele P Lambert; Jay H Herman; Terry B Gernsheimer; Keith R McCrae; Michael D Tarantino; James B Bussel
Journal: Transfusion Date: 2011-10-07 Impact factor: 3.157

3. Clinical Practice Updates in the Management Of Immune Thrombocytopenia.

Authors: Ayesha M Khan; Halina Mydra; Ana Nevarez
Journal: P T Date: 2017-12

4. A novel laboratory technique demonstrating the influences of RHD zygosity and the RhCcEe phenotype on erythrocyte D antigen expression.

Authors: Patrick T McGann; Jenny M Despotovic; Thad A Howard; Russell E Ware
Journal: Am J Hematol Date: 2011-11-25 Impact factor: 10.047

5. Investigation of whether the acute hemolysis associated with Rh(o)(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model.

Authors: Ann Reed Gaines; Hallie Lee-Stroka; Karen Byrne; Dorothy E Scott; Lynne Uhl; Ellen Lazarus; David F Stroncek
Journal: Transfusion Date: 2009-02-09 Impact factor: 3.157

Review 6. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.

Authors: B M Kumpel
Journal: Clin Exp Immunol Date: 2008-08-22 Impact factor: 4.330

A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP).

Review 1. Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Review 2. RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).

3. Clinical Practice Updates in the Management Of Immune Thrombocytopenia.

4. A novel laboratory technique demonstrating the influences of RHD zygosity and the RhCcEe phenotype on erythrocyte D antigen expression.

5. Investigation of whether the acute hemolysis associated with Rh(o)(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model.

Review 6. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.

Review 7. Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives.

8. Immune Thrombocytopenic Purpura (ITP) Following Natural COVID-19 Infection.

9. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia.

Review 10. Advances in Diagnosis and Treatments for Immune Thrombocytopenia.